3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
103
Neoplasms, Plasma Cell
11
Immunoglobulin Light-chain Amyloidosis
11
Recurrence
10
Leukemia, Myeloid, Acute
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm, Residual
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Paraproteinemias
3
Neoplasms
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Waldenstrom Macroglobulinemia
2
Smoldering Multiple Myeloma
2
Prostatic Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Plasma Cell
2
Hodgkin Disease
2
Hematologic Diseases
2
Corneal Diseases
2
Blood Protein Disorders
2
Amyloidosis
2
Acute Kidney Injury
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Renal Insufficiency
1
Proteostasis Deficiencies
1
Primary Myelofibrosis
1
Plasmacytoma
1
Interventions
Lenalidomide
3
Dexamethasone
3
ixazomib
2
dexamethasone acetate
2
dexamethasone 21-phosphate
2
auricularum
2
Radiotherapy
2
Calcium Dobesilate
2
pomalidomide
1
daratumumab
1
cc-486
1
Thalidomide
1
Sodium Selenite
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
Panobinostat
1
Melphalan
1
Immunotherapy, Adoptive
1
Gemcitabine
1
Drug Combinations
1
Busulfan
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Plasmacytoma
×
daratumumab
×
Clear all
NCT04065308
2019-08-22
Dara_DCEP
Seoul National University Hospital
Phase 2
Unknown
33 enrolled